Trevi Therapeutics, Inc.
16.64USD
-0.1800 (-1.07%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.13▼ | $-0.12 | 0 | 1 |
| Next quarter | $-0.14▼ | $-0.14 | 1 | 2 |
| Current year | $-0.48▼ | $-0.45 | 1 | 7 |
| Next year | $-0.58▼ | $-0.52 | 1 | 5 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.11 | $-0.11 | -0.00 (-0.9%) |
| 2026-03-31 | $-0.07 | $-0.09 | -0.02 (-23.3%) |
| 2025-12-31 | $-0.1 | $-0.06 | +0.04 (+37.2%) |
| 2025-09-30 | $-0.1 | $-0.08 | +0.02 (+19.1%) |
86 ratings from 18 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Jones Trading | Maintained | Buy | $24 $28 | Aug 14, 2026 |
| Oppenheimer | Maintained | Outperform | $24 $25 | Aug 7, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $25 $30 | Aug 7, 2026 |
| BMO Capital | Initiated | Outperform | $36 | Jul 21, 2026 |
| B. Riley Securities | Maintained | Buy | $21 $31 | Jul 20, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $21 $24 | Jul 20, 2026 |
| Needham | Reiterated | Buy | $23 | May 20, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $21 | May 6, 2026 |
| Needham | Maintained | Buy | $24 $23 | May 6, 2026 |
| D. Boral Capital | Maintained | Buy | $19 | Apr 17, 2026 |
| Jones Trading | Maintained | Buy | $25 $24 | Mar 19, 2026 |
| Morgan Stanley | Maintained | Overweight | $19 $18 | Mar 18, 2026 |
| D. Boral Capital | Maintained | Buy | $19 | Mar 18, 2026 |
| Needham | Maintained | Buy | $22 $24 | Mar 18, 2026 |
| D. Boral Capital | Maintained | Buy | $19 | Mar 9, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $21 | Mar 9, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $21 | Jan 9, 2026 |
| D. Boral Capital | Maintained | Buy | $19 | Jan 8, 2026 |
| Stifel | Maintained | Buy | $15 $18 | Dec 19, 2025 |
| Leerink Partners | Maintained | Outperform | $13 $16 | Nov 20, 2025 |
| D. Boral Capital | Maintained | Buy | $19 | Nov 14, 2025 |
| Oppenheimer | Maintained | Outperform | $23 $24 | Nov 14, 2025 |
| Morgan Stanley | Maintained | Overweight | $18 $19 | Nov 14, 2025 |
| Clear Street | Maintained | Buy | $11 $21 | Nov 14, 2025 |
| Morgan Stanley | Initiated | Overweight | $18 | Aug 21, 2025 |
23 filings from 14 insiders · 0 buy / 0 sell over 6m
Officers and directors of TRVI, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| GALLETTA CHRISTOPHEROfficer | Exercise | 4.2k | $0.51 | $2k | Dec 2, 2025 |
| BASKETT FORESTBeneficial Owner of more than 10% of a Class of Security | Exerciseindirect | 1.85M | $1.37 | $2.54M | Apr 17, 2025 |
| WALKER PAUL EDWARDBeneficial Owner of more than 10% of a Class of Security | Exerciseindirect | 1.85M | $1.37 | $2.54M | Apr 17, 2025 |
| FLORENCE ANTHONY A JRBeneficial Owner of more than 10% of a Class of Security | Exerciseindirect | 1.85M | $1.37 | $2.54M | Apr 17, 2025 |
| BEHBAHANI ALIBeneficial Owner of more than 10% of a Class of Security | Exerciseindirect | 1.85M | $1.37 | $2.54M | Apr 17, 2025 |
| MAKHZOUMI MOHAMADBeneficial Owner of more than 10% of a Class of Security | Exerciseindirect | 1.85M | $1.37 | $2.54M | Apr 17, 2025 |
| NEW ENTERPRISE ASSOCIATES 16, L.P.Beneficial Owner of more than 10% of a Class of Security | Exerciseindirect | 1.85M | $1.37 | $2.54M | Apr 17, 2025 |
| CHANG CARMENBeneficial Owner of more than 10% of a Class of Security | Exerciseindirect | 1.85M | $1.37 | $2.54M | Apr 17, 2025 |
| SANDELL SCOTT DBeneficial Owner of more than 10% of a Class of Security | Exerciseindirect | 1.85M | $1.37 | $2.54M | Apr 17, 2025 |
| SCIASCIA THOMAS ROfficer | Sell | 2.6k | $6.60 | $17k | Mar 25, 2025 |
| SCIASCIA THOMAS ROfficer | Exercise | 2.6k | $1.43 | $4k | Mar 25, 2025 |
| GOOD JENNIFER LChief Executive Officer | Sell | 5.3k | $6.58 | $35k | Mar 21, 2025 |
| GOOD JENNIFER LChief Executive Officer | Exercise | 5.3k | $1.43 | $8k | Mar 21, 2025 |
| SIMON FARRELLOfficer | Sell | 81.3k | $6.73 | $549k | Mar 10, 2025 |
| SIMON FARRELLOfficer | Exercise | 112.6k | $0.51 | $322k | Mar 10, 2025 |
| DELFINI LISAChief Financial Officer | Exercise | 6.0k | $0.51 | $3k | Jan 8, 2025 |
| GALLETTA CHRISTOPHEROfficer | Exercise | 15.0k | $0.51 | $8k | Dec 13, 2024 |
| GOOD JENNIFER LChief Executive Officer | Sell | 6.1k | $3.03 | $18k | Sep 9, 2024 |
| GOOD JENNIFER LChief Executive Officer | Exercise | 6.1k | $1.43 | $9k | Sep 9, 2024 |
| GOOD JENNIFER LChief Executive Officer | Sell | 55.1k | $3.02 | $170k | Sep 5, 2024 |
No analyst notes on TRVI yet.
Analyst Ratings
11 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 9 | 0 | 0 | 0 | Buy1.82 |
| 1 mo ago | 2 | 9 | 0 | 0 | 0 | Buy1.82 |